Download PDF
Deutsche Zeitschrift für Onkologie 2011; 43(1): 4-10
DOI: 10.1055/s-0030-1257604
Forschung
© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Diagnostik und Therapie maligner Ovarialtumoren

Barbara Schmalfeldt
Further Information

Publication History

Publication Date:
06 April 2011 (online)

    Permissions and Reprints

Zusammenfassung

Das Ovarialkarzinom ist das zweithäufigste Genitalkarzinom der Frau, verursacht jedoch die meisten Todesfälle von allen gynäkologischen Tumoren. Bei 75 % der Patientinnen liegt bei Diagnosestellung bereits ein fortgeschrittenes Stadium (FIGO IIB–IV) vor. Tumorstadium, Alter, Allgemeinzustand und postoperativer Tumorrest sind signifikante prognostische Parameter für das Überleben von Patientinnen mit Ovarialkarzinom. Entscheidend für das Überleben sind die systematische Exploration des gesamten Abdomens mit Entnahme multipler Peritonealbiopsien und die vollständige Entfernung aller makroskopisch erkennbaren Tumormanifestationen. Wesentliche operative und therapeutische Maßnahmen bei frühem und fortgeschrittenem Ovarialkarzinom werden in diesem Übersichtsartikel dargestellt.

Summary

The ovarian carcinoma is the second-most frequent genital carcinoma of the woman, nevertheless, causes most deaths of all gynaecological tumours. With 75 % of the patients an advanced stage (FIGO IIB to IV) is initially diagnosed. Tumour stage, age, general situation and postal-surgical tumour rest are significant prognostic parametres for the survival of patients with ovarian carcinoma. Decisively for survival are the systematic exploration of the abdomen and the complete resection of all macroscopic tumour manifestations. Essential surgical and therapeutic interventions of early and advanced ovarian carcinoma are shown in this overview article.

Schlüsselwörter

Ovarialkarzinom - Rezidiv - Peritonealkarzinose - Prognosefaktoren - Operation - Therapie

Keywords

Ovarian carcinoma - recurrence - peritoneal carcinosis - prognostic factors - operation - therapy

Literatur

  • 01 Abushahin F, Singh D K, Lurain J R et al.. Weekly topotecan for recurrent platinum resistant ovarian cancer.  Gynecol Oncol. 2008;  108 (1) 53-7
    Google Scholar
  • 02 Aletti G D, Dowdy S C, Podratz K C, Cliby W A. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.  Gynecol Oncol. 2006;  100 283-7
    Google Scholar
  • 03 Armstrong D K, Bundy B N, Baergen R et al.. Randomized phase III study of intravenous (IV) paclitaxel and cisplatin versus IV paclitaxel, intraperitoneal (IP) cisplatin and IP paclitaxel in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 172).  Proc Am Soc Clin Oncol. 2008;  803
    Google Scholar
  • 04 Baggerly K A, Morris J S, Edmonson S R, Coombes K R. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer.  J Natl Cancer Inst. 2005;  97 307-9
    Google Scholar
  • 05 Bell J, Brady M F, Young R C et al.. Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.  Gynecol Oncol. 2006;  102 (3) 432-9
    Google Scholar
  • 06 Benedetti-Panici P B, Maggioni A, Hacker N et al.. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.  J Natl Cancer Inst. 2005;  97 560-6
    Google Scholar
  • 07 du Bois A, Rochon J, Lamparter C, Pfisterer J. Ovarialkarzinom – Versorgungsstruktur und -qualität in Deutschland 2001–2004.  Der Frauenarzt. 2005;  46 (7) 560-7
    Google Scholar
  • 08 du Bois A et al.. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour les Etudes des Cancers de l'Ovaire (GINECO).  Cancer. 2009;  115 (6) 1234-44
    Google Scholar
  • 09 du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline tumors of the ovary. A systematic review.  GebFra. 2009;  69 (9) 807-33
    Google Scholar
  • 10 du Bois A, Reuss A, Harter P et al.. Potential role of lymphadnectomy in advanced ovarian cancer: A combined exploratory ananlysis of three prospectively randomized phase III multicenter trials.  J Clin Oncol. 2010;  28(10) 1733-9
    CrossrefPubMedGoogle Scholar
  • 11 Bristow R E et al.. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.  J Clin Oncol. 2002;  20 (5) 1248-59
    CrossrefPubMedGoogle Scholar
  • 12 Bristow R E, Chi D S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis.  Gynecol Oncol. 2006;  103 1070-6
    CrossrefPubMedGoogle Scholar
  • 13 Bristow R E, Eisenhauer E L, Santillan A, Chi D S. Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction.  Gynecol Oncol. 2007;  104 480-90
    CrossrefPubMedGoogle Scholar
  • 14 Burger R A, Sill M W, Monk B J et al.. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.  J Clin Oncol. 2007;  25 (33) 5165-71
    CrossrefPubMedGoogle Scholar
  • 15 Cannistra S A, Matulonis U A, Penson R T et al.. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.  J Clin Oncol. 2007;  25 (33) 5180-6
    CrossrefPubMedGoogle Scholar
  • 16 Chi D S, Eisenhauer E L, Lang J H et al.. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIc epithelial ovarian carcinoma (EOC).  Gynecol Oncol. 2006;  103 559-64
    CrossrefPubMedGoogle Scholar
  • 17 Covens A et al.. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer.  Gynecol Oncol. 2002;  85 (1) 71-80
    CrossrefPubMedGoogle Scholar
  • 18 Dressman H K, Berchuck A, Chan G et al.. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.  J Clin Oncol. 2007;  25(5) 517-25
    CrossrefPubMedGoogle Scholar
  • 19 Eisenhauer E L, Abu-Rustum N R, Sonoda Y et al.. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.  Gynecol Oncol. 2006;  103 1083-90
    CrossrefPubMedGoogle Scholar
  • 20 Fujiwara K, Nagao S, Kigawa J et al.. Comparative phase II study of intraperitoneal (IP) versus intravenous (IV) carboplatin administration with IV paclitaxel in patients with bulky residual disease after primary debulking surgery for epithelial ovarian or primary peritoneal cancer: A Sankai Gynecology Study Group (SGSG) study.  J Clin Oncol. 2007;  25(18S) 5584
    CrossrefPubMedGoogle Scholar
  • 21 Goff A B, Mandel L S, Drescher C W et al.. Development of an Ovarian cancer symptom index.  Cancer. 2006;  109 221-7
    PubMedGoogle Scholar
  • 22 Greer B E, Bundy B N, Ozols R F. Implications of second-look laparotomy in the context of optimally resected Stage III ovarian cancer: A non randomized comparison using an explanatory analysis: A GOG Study.  Gynecol Oncol. 2005;  99 71-9
    CrossrefPubMedGoogle Scholar
  • 23 Harter P, du Bois A, Hahmann M et al.. Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee; AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial.  Ann Surg Oncol. 2006;  13(12) 1702-10
    CrossrefPubMedGoogle Scholar
  • 24 Heintz A P, Odicino F, Maisonnueve P et al.. Carcinoma of the Ovary.  Int J Gynecol Obstet. 2006;  95 (S1) S161-S92
    CrossrefPubMedGoogle Scholar
  • 25 Katsumata N et al.. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.  Lancet. 2009;  374 (9698) 1331-8
    CrossrefPubMedGoogle Scholar
  • 26 Kauff N D, Barakat R R. Risk reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.  J Clin Oncol. 2007;  25 2921-7
    CrossrefPubMedGoogle Scholar
  • 27 Kommission Ovar der Arbeitsgemeinschaft Gynäkologische Onkologie e. V. in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e. V. sowie in der Deutschen Krebsgesellschaft e. V Hrsg.. Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. München, Wien, New York: Zuckschwerdt; 2007
    Google Scholar
  • 28 Lu K H, Patterson A P, Wang L et al.. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.  Clin Canc Res. 2004;  10 3291-300
    CrossrefPubMedGoogle Scholar
  • 29 Olivier R I, Lubsen-Brandsma M A, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high risk women cannot prevent the diagnosis of advanced ovarian cancer.  Gynecol Oncol. 2006;  100 20-6
    CrossrefPubMedGoogle Scholar
  • 30 Pfisterer J, du Bois A, Sehouli J et al.. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.  Ann Oncol. 2006;  17(10) 1568-77
    CrossrefPubMedGoogle Scholar
  • 31 Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al.. Pegylated liposoamal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum sensitive ovarian cancer in late relapse.  J Clin Oncol. 2010;  28(20) 3323-9
    CrossrefPubMedGoogle Scholar
  • 32 Risch H A, McLaughlin J R, Cole D E et al.. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.  Hum Genet. 2001;  68(3) 700-10
    CrossrefPubMedGoogle Scholar
  • 33 Sabbatini P, Dupont J, Aghajanian C et al.. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.  Clin Cancer Res. 2006;  12(18) 5503-10
    CrossrefPubMedGoogle Scholar
  • 34 Salani R, Santillan A, Zahurak M L et al.. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.  Cancer. 2007;  109(4) 685-91
    CrossrefPubMedGoogle Scholar
  • 35 Schmalfeldt B Hrsg.. Manual Maligne Ovarialtumoren. Empfehlungen zur Diagnostik, Therapie und Nachsorge. Herausgegeben vom Tumorzentrum München. 9. Aufl. München: Zuckschwerdt; 2010
    Google Scholar
  • 36 Van Nagell J R, De Priest P D, Ueland F R et al.. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened.  Cancer. 2007;  109 1887-96
    CrossrefPubMedGoogle Scholar
  • 37 Vasey P A, Jayson G C, Gordon A et al.. Phase III randomized trial of Docetaxel- Carboplatin versus Paclitaxel-Carboplatin as first-line chemotherapy for ovarian carcinoma.  J Natl Cancer Inst. 2004;  96 1682-91
    CrossrefPubMedGoogle Scholar
  • 38 Vergote I, Trope C G, Amant F et al.. for the European Organization for Research and Treatment of Cancer – Gynecological Cancer Group and the NCIC Clinical Trials Group – a Gynecologic Cancer Intergroup Collaboration. Neoadjuvant Chemotherapy versus primary surgery in stage IIIC or IV ovarian cancer.  N Engl J Med. 2010;  363 943-53
    CrossrefPubMedGoogle Scholar
  • 39 Winter-Roach B A, Kitchener B A, Dickinson H O. Adjuvant post-surgery chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of Systematic Reviews; 2009 Issue 1. Art. No: CD004706. DOI:10.1002/14651858.CD004706.pub2
    Google Scholar
  • 40 Zhang H, Kong B, Qu X et al.. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.  Gynecol Oncol. 2006;  102(1) 61-6
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse

Prof. Dr. Barbara Schmalfeldt

Frauenklinik der Technischen Universität München

Ismaninger Str. 22

81675 München

Email: barbara.schmalfeldt@lrz.tum.de

      >